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Abstract
Due to its high incidence breast cancer is still a major 
health problem worldwide since, although a high percent-
age of patients can be effectively cured there are still some 
concerns in patients’ management. Several new biomarkers 
and potential targets for therapy have been identified but 
still the effects on patients’ outcome is not fully satisfac-
tory. In the last years it was shown that potassium channels 
belonging to the different subfamilies are overexpressed in 
primary breast cancers and several associations with clinic-
pathological features and outcome have been investigated. 
In this context, altered ion channels expression may be use-
ful for diagnostic and therapeutic purposes. 
This short review focuses on the expression and clinical 
relevance of potassium channels in breast cancer, recapitu-
lating past and recent findings in translational research. 
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Introduction
Breast Cancer (BC) is often described as a single disease but 
it is well known that it is quite heterogeneous with differences 
in clinical features, prognosis and response to treatment [1]. 
The heterogeneity of BC is reflected in the differences in prog-
nosis and treatment options, therefore several studies have 
been focused on defining the biological features of BCs to bet-
ter stratify the patients into risk groups to be treated with differ-
ent regimens. The currently used classification of BCs is based 
on the detection of four biomarkers: the estrogen and proges-
terone receptors (ER, PgR), the Human Epidermal Growth Fac-
tor Receptor 2 (HER2) and the proliferation index (evaluated 
through Ki67 staining). Based on such molecular classification, 
five main BC subtypes (Luminal A, Luminal B, HER2-positive, 
Triple-negative and Normal-like) with different prognosis can be 
distinguished. To better manage BC patients, the identification 
of new diagnostic tools as well as novel targets for therapy is 
mandatory. Through these studies several potential biomarkers 
have been identified. According to the NCI Dictionary of Cancer 
Terms, a biomarker is defined as “a biological molecule found 
in blood, other body fluids, or tissues that is a sign of a normal 
or abnormal process, or of a condition or disease”. Biomarkers 
can be used for diagnostic, prognostic and predictive purposes 
in oncology. 
Data gathered so far suggest that several ion channels could 
serve as biomarkers since they are frequently overexpressed in 
BC and such expression associates with clinico-pathological fea-
tures (Table 1).
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Ion Channels
It is now well known that ion channels are expressed in dif-
ferent human tumors modulating several cell processes. Thus, 
ion channels could be proposed as novel cancer biomarkers, af-
ter being validated in the clinical setting.
Ion channels are transmembrane proteins that regulate ion 
fluxes through a central pore. Ion channels are generally pres-
ent on the cell membrane in three different conformations (Fig-
ure 1): the “open” conformation allows the ions flow through 
the channel, while when the channel is in the “closed” state 
the ion flux is avoided. The third conformational status is the 
“inactivated” one, in which the channel is open but unable of 
letting ions flow. 
The localization at the plasma membrane level suggests that 
ion channels might be good potential biomarkers since their de-
tection might be easily performed for example by IHC and other 
molecular techniques; moreover they might also be blocked 
with specific drugs and antibodies. Several studies have been 
published in the last years to evaluate ion channels expression 
and potential use in BC management. 
Among ion channels, potassium channels are key players that 
have been proven to be deregulated in several human cancers. 
Potassium channels belong to a multi-gene family and sev-
eral subfamilies have been identified (Figure 2): voltage-gated 
potassium channels, inward rectifiers, two-pore domains and 
calcium-activated channels (reviewed in [2]). Voltage-gated po-
tassium channels are composed of four subunits surrounding an 
aqueous pore. Each subunit is made of six transmembrane do-
mains (S1-S6): S4 is the voltage sensor while a loop between S5 
and S6 defines the pore (P). Inward rectifiers are made of four 
subunits and each of them contains two transmembrane do-
main, linked by a P-loop. Two-pore domains channels are com-
posed of four transmembrane domains and two regions that as-
semble to form the aqueous pore. Calcium-activated potassium 
channels represent a family with two groups of proteins: small- 
and intermediate- conductance (SK) and high-conductance 
potassium channels (BK). The SK channels are tetramers each 
composed by six transmembrane domains (S1-S6) with the cen-
tral pore lying in the S5-S6 region; the BK channels are generally 
tetramers made of α (forming the pore) and β subunits. 
Potassium channels in breast cancer
From different studies performed over the last 20 years, sev-
eral K+ channels have been proven to be overexpressed in pri-
mary BC and BC cell lines. A detailed list of potassium channels 
that have been proven to be expressed in BC (and their role, if 
known) is reported in (Table 1). 
Long ago it was shown that a member of the voltage-gated 
family (Kv1.1, also known as KCNA1) is expressed in BC cell lines 
and it is involved in cell proliferation [3].
Kv1.3 channels, encoded by KCNA3 gene, are expressed in 
BC cell lines and are involved in apoptosis and proliferation [4]. 
Kv1.3 channels are also expressed in primary BC and their ex-
pression is associated with poor prognosis [4] and advanced 
stage [5]. 
Another member of the Voltage-gated subfamily, Kv4.1, is 
also expressed in BC cell lines and regulates cell proliferation 
[6].
Kv10.1 (also known as Eag1 or KCNH1) is a voltage-gated 
potassium channel that is expressed in human tumors while it 
is absent in the corresponding normal tissues [7] and long ago 
it was shown that in BC cell line MCF-7 Kv10.1 is one of the 
channels involved in proliferation and cell cycle progression 
[8] and migration [9]. Moreover, high Kv10.1 levels have been 
found in human BCs [10] both at the mRNA and protein levels 
by means of Real Time PCR and IHC, respectively. Different Au-
thors showed that Kv10.1 is more expressed in invasive-ductal 
carcinomas than in fibro adenomas [11] and it was shown that 
calcitriol (that has anti-proliferative effects) reduces Kv10.1 ex-
pression by a mechanism based on vitamin D receptor. The same 
group also demonstrated that the combination of calcitriol and 
astemizole has a higher efficacy in reducing Kv10.1 expression 
[12]. More recently, it was shown that Kv10.1 is expressed at 
higher levels in TN BCs with respect to other molecular sub-
types and that it correlates with tumor dimensions, stage and 
lymph node involvement [13]. 
Recently, it was shown that in BC cells SKBR3 and MDA-MB-
231 the exposure to Kv11.1 channel agonist (NS1643) causes the 
cell cycle to stop in G0/G1 and induces cell senescence [14]. It 
was also demonstrated that Kv11.1 stimulates p21waf/cip tran-
scription in BC cell lines [15]. The same group, analyzing public 
datasets, also showed that KCNH2 gene is overexpressed in BC 
[16]. To our knowledge, no data have been published regard-
ing Kv11.1 protein expression in primary BC yet. We recently 
demonstrated that Kv11.1 protein is over-expressed in primary 
BC and found interesting correlations with clinico-pathological 
features and outcome [17]. These data might be of great clini-
cal interest since Tamoxifen (used for BC treatment) was shown 
to block Kv11.1 currents [18], therefore it could be argued that 
Kv11.1 might serve as a therapeutic target and predictor of re-
sponse to therapy. 
Among the members of the Inward Rectifiers subfamily, it 
was demonstrated that Kir3.1 (also known as KCNJ3) channels 
are expressed in BC and positively correlate with the presence 
of lymph node metastases [19]. More recently it was also shown 
that Kir3.1 is associated with ER expression and represents an 
independent indicator of poor prognosis in ER+ tumors [20]. 
Other members of the Inward Rectifier subfamily are involved 
in cell cycle progression (Kir2.2, Kir6.1 and Kir6.2) [21,22], apop-
tosis and proliferation (Kir6.1 and Kir6.2) [22].
Figure 1: Schematic drawing of an ion channel in the 
“open” (left), “closed” (middle) and “inactivated” (right) con-
formational states.
Figure 2: Potassium channels sub-families.
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A member of the Two-pore subfamily (K2P5.1 also known as 
KCNK5 or TASK2) regulates BC proliferation [23] and its expres-
sion is induced by estrogens in ER+ BC cells, thus it was sug-
gested as a potential therapeutic target for ER+ patients [23]. 
The KCNK9 gene encoding for K2P9.1 (also known as KCNK9 or 
TASK3), a member of, is amplified in BC and the corresponding 
protein is over-expressed. Such protein regulates cell migration 
in BC cell lines [24].
Three members of the Calcium-activated subfamily have 
been shown to be expressed in BC. KCa1.1 is expressed in BC 
cell lines and regulates apoptosis and migration [25]; in primary 
BCs, KCa1.1 expression correlates with ER [26], the occurrence 
of brain metastases [27], high stage, nuclear grade, prolifera-
tion and poor prognosis [28]. KCa2.3 regulates BC cell migration 
[29] while the expression of KCa3.1 (also known as KCNN4) has 
been demonstrated in BC cell lines, in which it is involved in mi-
gration and proliferation [30] while in primary BCs it correlates 
with high grade tumors with negative lymph nodes [31].
Finally, in a paper published in 2013 [32], a molecular signa-
ture of ion channels in BC was defined. Briefly, 280 ion chan-
nel genes were collected and eight independent microarray BC 
datasets from different countries (Singapore, France, Germany, 
Netherlands, Sweden, Taiwan and the United States) were 
analyzed. 22 differentially expressed ion channel genes (5 up-
regulated and 17 down-regulated) were identified in p53 mu-
tant tumors with respect to wild type ones. The second point of 
this study was the identification of differentially expressed ion 
channel genes between ER+ and ER- BC patients. Through this 
analysis it was shown that 16 genes were up-regulated and 8 
genes were down-regulated in ER+ patients. Of these 24 genes, 
19 overlapped with the differentially expressed genes identified 
in the comparison between mutant and wild type p53 patients 
and, among these common genes, it emerged that all the down-
regulated genes in ER+ patients were up-regulated in patients 
bearing p53 mutations. The third point of the study was to in-
vestigate the possible relationships between ion channel gene 
expression and histological tumor grade and a correlation was 
demonstrated for 30 ion channel genes. Based on these find-
ings, the Authors defined these ion channel genes as the “IC30 
gene signature” and it was proven to be a good and indepen-
dent biomarker to predict clinical outcome in BC patients. More 
recently, an in silico analysis of public datasets was performed 
[16] and the high expression of KCNH2 was demonstrated. 
These data are quite interesting since they are in accordance 
with our recent findings concerning the expression and clinical 
relevance of Kv11.1 channels in BC primary samples [17].
Potassium channels as therapeutic targets in breast cancer
In the recent years several evidences have been gathered 
concerning the potential use of potassium channels (together 
with other ion channels) as therapeutic targets. In this field, 
two of the most studied potassium channels are represented 
by Kv10.1 and Kv11.1, as described above. It was shown in vivo, 
that using astemizole (a Kv10.1 blocker already used in the clini-
cal setting) significantly reduced in vivo growth of MDA-MB435S 
xenografts [33]. More interestingly, it was shown that the com-
bined treatment with astemizole and calcitriol resulted in sharp 
reduction of the tumor masses in T-47D xenografts as well as in 
mouse models obtained with primary BCs [12].
The importance and role of Kv11.1 in several human solid 
cancers has been clearly defined and described also as a poten-
tial target for therapy [34,35] and it was shown that the combi-
nation of specific blockers of the channels together with drugs 
already used in the clinical practice (such as Bevacizumab) al-
most completely inhibit tumor growth in in vivo models [35]. 
More recently, it was shown that metastasis of breast cancer 
cells in vivo was reduced when the Kv11.1/β1 integrin complex 
(present in cancer cells but not in the heart) was broken [36], 
thus opening the possibility of exploiting also the Kv11.1/β1 in-
tegrin complex as a target for therapy.
Conclusion
The possibility of including into routine clinical practice a 
panel of biomarkers that might give more information useful 
for the management of BC patients is quite intriguing, although 
further validation studies are warranted. Among the genes in-
cluded in the “IC30 gene signature” there are some potassium 
channels already described as being involved in BC: in particu-
lar, KCNMA1 and KCNN4 genes have been found to be associ-
ated to more aggressive tumors (metastasizing to lymph nodes 
and brain, high grade and poor prognosis). This is of particu-
lar relevance since they are both Calcium-activated potassium 
channels and their deregulation in BC could be thus linked to 
calcium homeostasis.
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TNBC: Triple-Negative BC; ER: Estrogen Receptors; OS: Overall Survival; DFS: Disease-Free Survival
Tables
Table 1: Potassium channels sub-families.
Family
HGNC 
name
IUPHAR 
name
Alternative names Gene
Chromosome 
location
Cell lines Cinical correlations
Voltage-
gated
KCNA1 Kv1.1
RBK1, HUK1, MBK1, 
AEMK
KCNA1 12p13.32
Proliferation 
[1]
KCNA3 Kv1.3 MK3, HLK3, HPCN3 KCNA3 1p13.3
Apoptosis, pro-
liferation [2]
Poor prognosis, advanced stage [2,3]
KCND1 Kv4.1 - KCND1 Xp11.23
Proliferation 
[4]
KCNH1 Kv10.1 eag1 hEAG1 1q32.2
Proliferation 
[5], cell cycle 
progression [6], 
migration [7]
Overexpression [8], correlation with 
vit D receptor in invasive ductal 
carcinomas [9], poor prognosis [10], 
high expression in TNBC, association 
with stage, positive lymph nodes, 
higher expression in invasive ductal 
carcinomas [11]
KCNH2 Kv11.1 hERG1 hERG1 7q36.1
Cell senes-
cence [12], 
p21waf/cip 
transcription 
[13]
KCNH2 gene overexpression [14], 
correlation with molecular subtype, 
grading, ER, ki67 [15]
Inward 
Rectifier
KCNJ3 Kir3.1 GIRK1, KGA KCNJ3 2q24.1
Apical localiza-
tion [17]
Lymph node metastases [17], 
association with ER, independent 
prognostic factor (OS and DFS) [18]
KCNJ8 Kir 6.1  KCNJ8 12p12.1
Apoptosis, cell 
cycle, prolifera-
tion [19]
-
KCNJ11 Kir 6.2 BIR KCNJ11 11p15.1
Apoptosis, cell 
cycle, prolifera-
tion [19]
-
KCNJ12 Kir 2.2 Kir2.2v, IRK2, hIRK1 KCNJ12 17p11.2 Cell cycle [20] -
Two-pore 
Domain
KCNK5 K2P5.1 TASK2 KCNK5 6p21
Induced by 
estrogens in 
ERa-positive 
cell lines], pro-
liferation [21]
-
KCNK9 K2P9.1 TASK3 KCNK9 8q24.3 Migration [22] -
Calcium-
activated
KCNMA1 KCa1.1 mSLO1
KC-
NMA1
10q22
Migration [23], 
Apoptosis [24],
High stage, high grade, proliferation, 
poor prognosis [25], brain metasta-
ses [26]
KCNN3 KCa2.3 hSK3, SKCA3  1q21.3 Migration [27] -
KCNN4 KCa3.1 hSK4, hKCa4, hIKCa1 KCNN4 19q13.2
Proliferation 
[28]
High grade with negative lymph 
nodes [29]
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